Journal articleClin Cancer Res2020
Phase I/II Study of the Mesothelin-targeted Immunotoxin LMB-100 with Nab-Paclitaxel for Patients with Advanced Pancreatic Adenocarcinoma.
- Journal
- Clin Cancer Res
- Published
- 2 December 2019
- Citations
- 43
- Type
- Article
These are bibliographic fields. A study card, with population, design, endpoints and result direction each tied to a quote, is not in the data yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess. Only its metadata is loaded so far, so most questions will be declined.
Try
Grants 6
- Clinical Trials with Immunotoxins ZIABC010020↗
- Adoptive cell therapy for malignant mesothelioma and other mesothelin expressing ZIABC010816↗
- Precision Therapy to Target Pancreatic Ductal Adenocarcinoma ZIABC011652↗
- Using Clinical Pharmacology Principles to Develop New Anticancer Therapies ZICSC006537↗
- Signal Transduction Events and the Regulation of Cell Growth ZICSC006743↗
- Thoracic and Gastrointestinal Malignancies Branch Clinical Core ZIDBC011540↗